MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Woodline Partners LP

Woodline Partners LP boosted its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 26.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 293,535 shares of the company's stock after buying an additional 61,105 shares during the quarter. Woodline Partners LP owned approximately 0.46% of MoonLake Immunotherapeutics worth $15,895,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of MLTX. Deutsche Bank AG lifted its stake in shares of MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after buying an additional 338 shares in the last quarter. Birchview Capital LP purchased a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at approximately $217,000. KLP Kapitalforvaltning AS purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $244,000. PEAK6 LLC purchased a new position in MoonLake Immunotherapeutics during the 4th quarter worth $271,000. Finally, Mariner LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth $272,000. Institutional investors and hedge funds own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX traded up $0.29 during midday trading on Tuesday, hitting $39.22. 37,521 shares of the stock traded hands, compared to its average volume of 427,955. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The firm has a market capitalization of $2.51 billion, a PE ratio of -30.40 and a beta of 1.31. The business's 50 day moving average price is $38.41 and its two-hundred day moving average price is $44.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same quarter last year, the company posted ($0.22) earnings per share. As a group, equities research analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and set a $80.00 target price (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. Finally, Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $78.71.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.